Cadila Healthcare rose 5.07 per cent to Rs 336.65 after its parent Zydus Cadila received nod to market immuno-suppressant Mycophenolate Mofetil tablets and capsules (of 500mg and 200 mg) in the US.
Mycophenolate Mofetil tablets raked in an estimated $648 million in 2008, while the capsules netted $316 million. The stock opened at Rs 333 and made an intraday high/low of Rs 343/Rs 320.3. The scrip hit a 52-week high of Rs 347 and a low of Rs 222.
